Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
British Medical Bulletin
|
May 22, 2015
The genetics of Parkinson's disease
Stephen Mullin, Anthony Schapira
Methods in Molecular Biology (Clifton, N.J.)
|
June 18, 2004
Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease
Anthony Schapira, Raffaele Lodi
Molecular Neurobiology
|
January 31, 2013
α-Synuclein and mitochondrial dysfunction in Parkinson's disease
Stephen Mullin, Anthony Schapira
Expert Opinion on Pharmacotherapy
|
May 16, 2017
Safinamide for the treatment of Parkinson's disease
Ruth Mary deSouza, Anthony Schapira
Nature Reviews. Drug Discovery
|
August 19, 2005
Rasagiline
Anthony Schapira, Guy Bate, Peter Kirkpatrick
Expert Opinion on Therapeutic Targets
|
September 7, 2018
Chaperone-mediated autophagy as a therapeutic target for Parkinson disease
Philip Campbell, Huw Morris, Anthony Schapira
Neurobiology of Disease
|
October 22, 2019
Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
Shi-Yu Yang, Matthew Gegg, David Chau, et al.
Clinical Neuropharmacology
|
November 11, 2006
End-of-dose wearing off in Parkinson disease: a 9-question survey assessment
Mark Stacy, Robert Hauser, Wolfgang Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 24, 2026
Ambroxol for Parkinson's Disease
Marco Toffoli, Elisa Menozzi, Kashfia Chowdhury, et al.
Current Medical Research and Opinion
|
November 13, 2004
Diagnosing restless legs syndrome (RLS) in primary care
K Ray Chaudhuri, Alison Forbes, Donald Grosset, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
British Medical Bulletin
|
May 22, 2015
The genetics of Parkinson's disease
Stephen Mullin, Anthony Schapira
Methods in Molecular Biology (Clifton, N.J.)
|
June 18, 2004
Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease
Anthony Schapira, Raffaele Lodi
Molecular Neurobiology
|
January 31, 2013
α-Synuclein and mitochondrial dysfunction in Parkinson's disease
Stephen Mullin, Anthony Schapira
Expert Opinion on Pharmacotherapy
|
May 16, 2017
Safinamide for the treatment of Parkinson's disease
Ruth Mary deSouza, Anthony Schapira
Nature Reviews. Drug Discovery
|
August 19, 2005
Rasagiline
Anthony Schapira, Guy Bate, Peter Kirkpatrick
Expert Opinion on Therapeutic Targets
|
September 7, 2018
Chaperone-mediated autophagy as a therapeutic target for Parkinson disease
Philip Campbell, Huw Morris, Anthony Schapira
Neurobiology of Disease
|
October 22, 2019
Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
Shi-Yu Yang, Matthew Gegg, David Chau, et al.
Clinical Neuropharmacology
|
November 11, 2006
End-of-dose wearing off in Parkinson disease: a 9-question survey assessment
Mark Stacy, Robert Hauser, Wolfgang Oertel, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 24, 2026
Ambroxol for Parkinson's Disease
Marco Toffoli, Elisa Menozzi, Kashfia Chowdhury, et al.
Current Medical Research and Opinion
|
November 13, 2004
Diagnosing restless legs syndrome (RLS) in primary care
K Ray Chaudhuri, Alison Forbes, Donald Grosset, et al.
Page
of 2